United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

eumedica pharmaceuticals ag - buprenorphine hydrochloride - sublingual tablet - 400microgram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

eumedica pharmaceuticals ag - buprenorphine hydrochloride - sublingual tablet - 200microgram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

eumedica pharmaceuticals ag - buprenorphine hydrochloride - solution for injection - 300microgram/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - buprenorphine hydrochloride - sublingual tablet - 2mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - buprenorphine hydrochloride - sublingual tablet - 8mg

Australia - English - Department of Health (Therapeutic Goods Administration)

echo therapeutics pty ltd - buprenorphine hydrochloride, quantity: 0.216 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; mannitol; maize starch; povidone; magnesium stearate; citric acid; sodium citrate dihydrate - temgesic sublingual tablets are indicated for the short-term (not more than one week) management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain. temgesic is not recommended for use in children. temgesic does not have an approved role in opioid dependence rehabilitation programmes.

Australia - English - Department of Health (Therapeutic Goods Administration)

echo therapeutics pty ltd - buprenorphine hydrochloride, quantity: 324 microgram/ml (equivalent: buprenorphine, qty 300 microgram/ml) - injection, solution - excipient ingredients: glucose monohydrate; hydrochloric acid; water for injections - temgesic injection is indicated for the short-term (not more than one week) management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain. temgesic injection should be employed when sublingual administration is not practical e.g. pre- or peri-operatively. temgesic is not recommended for use in children. temgesic does not have an approved role in opioid dependence rehabilitation programmes.

United States - English - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - buprenorphine hydrochloride (unii: 56w8mw3en1) (buprenorphine - unii:40d3scr4gz), naloxone hydrochloride (unii: f850569pqr) (naloxone - unii:36b82amq7n) - suboxone sublingual film is indicated for treatment of opioid dependence . suboxone sublingual film should be used as part of a complete treatment plan that includes counseling and psychosocial support. suboxone sublingual film is contraindicated in patients with a history of hypersensitivity to buprenorphine or naloxone as serious adverse reactions, including anaphylactic shock, have been reported [see warnings and precautions (5.9)] . risk summary the data on use of buprenorphine, one of the active ingredients in suboxone sublingual film, in pregnancy, are limited; however, these data do not indicate an increased risk of major malformations specifically due to buprenorphine exposure. there are limited data from randomized clinical trials in women maintained on buprenorphine that were not designed appropriately to assess the risk of major malformations [see data]. observational studies have reported on congenital malformations among buprenorphine-exposed pregnancies, but were also not designed appropriatel

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - buprenorphine 100mg - injection (depot) - 100 mg/0.5ml - active: buprenorphine 100mg excipient: n-methyl-2-pyrrolidone polyglactin - sublocade is indicated for maintenance treatment of opioid dependence, within a framework of medical, social and psychological treatment.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - buprenorphine 300mg - injection (depot) - 300 mg/1.5ml - active: buprenorphine 300mg excipient: n-methyl-2-pyrrolidone polyglactin - sublocade is indicated for maintenance treatment of opioid dependence, within a framework of medical, social and psychological treatment.